We are thrilled to announce a new partnership with medical research charity LifeArc, bringing £30 million over five years to the UK DRI. With the Institute's strengths in discovery research and LifeArc’s translational expertise, we'll accelerate the path to new diagnostics, devices and treatments for dementia.
Read more
In another milestone for the Institute, we marked the official launch of the UK DRI Care Research & Technology Centre this month – a multi-million pound research facility to improve the lives of people living with dementia now.
Read more
Researchers led by Prof Adrian Isaacs (UK DRI Group Leader at UCL) have developed a way to monitor the success of therapies targeting the most common genetic cause of frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS).
Read more
Co-founded by Prof Chris Shaw (UK DRI at King's), AviadoBio will use a patented gene therapy platform to develop innovative treatments for people living with neurodegenerative diseases. If successful, these treatments have the potential to permanently correct faulty genes, transforming the lives of individuals affected.
Read more
The Dementia UK Ecosystem (DUKE) brings together leaders from the UK DRI, Dementias Platform UK, the National Institute for Health Research, the pharmaceutical industry, and funders to create a cohesive community, coordinating efforts to accelerate progress in tackling dementia.
Read more
Group Leader Dr Nir Grossman (UK DRI at Imperial) is leading a new trial using deep electrical currents applied to the brain of people living with Alzheimer's disease. The team are recruiting participants over the next year.
Read more
We have a clearly defined vision at the UK DRI to develop effective therapeutics, diagnostics and technologies for people living with dementia. Alongside building our disease knowledge over the coming years, we will also make progress in translating these discoveries into the clinic.
Translation and innovation
We accelerate, innovate, deepen and broaden discovery science in dementia, with the goal of filling the huge knowledge gap in this field. We exist to bring forward the day when research benefits people living with and those at risk of dementia.
Read our science vision
Our efforts to increase the diversity of our team, ensure inclusion and promote equality of opportunity, align with our vision for the UK DRI’s Institute culture and identity as a world-leader in dementia research.
Equity, Diversity and Inclusion
We study a range of neurodegenerative disorders that cause dementia. Many of them share fundamental disease mechanisms and characteristics, and greater understanding gained in one can often benefit others. To ensure we capitalise on diverse expertise, approaches and perspectives, we have established cross-centre themes.
Research themes
